All In Biotech

Drug Trial Radar · NCT04582344

Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)

Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated

Last checked: Nov 20, 2026Latest source record: May 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 10,214 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,214

Actual

Start

Sep 14, 2020

Primary completion

Jun 30, 2022

Study completion Jul 27, 2022

Sponsor

Lead sponsor
Health Institutes of TurkeyGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Oct 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blinded, and placebo controlled phase III clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental vaccine in healthy adults aged 18\~59 Years.

Conditions

  • COVID-19

Interventions

  • CoronaVacBiological

    Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14

  • PlaceboBiological

    Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19Time frame: 2 weeks after the second dose of vaccination

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Çukurova University Faculty of Medicine, Department of Infectious Diseases

    Adana, Turkey (Türkiye)

  • Hacettepe University Faculty of Medicine Department of Infections Diseases and Clinical Microbiology

    Ankara, Turkey (Türkiye)

  • T.C Ministry of Health Ankara Provincial Health Directorate Health Sciences University Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital

    Ankara, Turkey (Türkiye)

  • Akdeniz University Faculty of Medicine, Department of Infectious Diseases

    Antalya, Turkey (Türkiye)

  • Bursa Uludağ University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    Bursa, Turkey (Türkiye)

  • Dicle University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    Diyarbakır, Turkey (Türkiye)

  • Gaziantep University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    Gaziantep, Turkey (Türkiye)

  • Acıbadem Atakent Hospital, Infectious Diseases and Clinical Microbiology

    Istanbul, Turkey (Türkiye)

  • Cerrahpaşa Faculty of Medicine, Department of Internal Medicine - Department of Infectious Diseases and Clinical Microbiology

    Istanbul, Turkey (Türkiye)

  • Istanbul Medipol University Faculty of Medicine, Department of Internal Medicine

    Istanbul, Turkey (Türkiye)

  • Istanbul University Istanbul Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    Istanbul, Turkey (Türkiye)

  • T.R. Ministry of Health Istanbul Provincial Health Directorate Marmara Univesity Istanbul Pendik Education and Research Hospital

    Istanbul, Turkey (Türkiye)

  • T.R. Ministry of Health Istanbul Provincial Health Directorate Prof. Dr. Cemil Taşçıoğlu City Hospital, Infectious Diseases Clinic

    Istanbul, Turkey (Türkiye)

  • T.R. Ministry of Health Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital

    Istanbul, Turkey (Türkiye)

  • University of Health Sciences İstanbul Ümraniye Training and Research Hospital

    Istanbul, Turkey (Türkiye)

  • Ege University Faculty of Medicine Hospital, Department of Infectious Diseasesaculty of Medicine Hospital, Department of Infectious Diseases

    Izmir, Turkey (Türkiye)

  • Republic Of Turkey Ministry Of Health Izmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital

    Izmir, Turkey (Türkiye)

  • T.R. Ministry of Health İzmir Provincial Health Directorate İzmir Health Sciences University Tepecik Training and Research Hospital, Infectious Diseases

    Izmir, Turkey (Türkiye)

  • T.R. Ministry of Health Kayseri City Training and Research Hospital, Infectious Diseases and Clinical Microbiology Department

    Kayseri, Turkey (Türkiye)

  • Kocaeli University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    Kocaeli, Turkey (Türkiye)

  • Malatya İnönü University Faculty of Medicine, Department of Infectious Diseases

    Malatya, Turkey (Türkiye)

  • Karadeniz Technical University Medical Faculty Hospital, Department of Infectious Diseases and Clinical Microbiology

    Trabzon, Turkey (Türkiye)

  • T.R. Ministry of Health Ankara City Hospital, Infectious Diseases and Clinical Microbiology Clinic

    Ankara, Turkey Region, Turkey (Türkiye)

  • T.R. Ministry of Health Ankara Provincial Health Directorate Ankara Training and Research Hospital, Infectious Diseases

    Ankara, Turkey Region, Turkey (Türkiye)

  • Ankara University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    Ankara, Turkey Region, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.